|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study显示文摘AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis(UC) and to identify predictors of response.METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician's global clinical assessment(PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database.RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the average age. Thirty percent had left-sided UC(E2) and 70% had extensive UC(E3). All patients had an endoscopic Mayo score of 2 or 3 at baseline. Twenty-seven point three percent were anti-tumor necrosis factor(TNF) treatment na?ve, whereas 72.7% had previously received infliximab and/or adalimumab. Sixty-nine point seven percent showed clinical response and were steroid-free at wk 14(a decrease from baseline in the partial Mayo score of at least 3 points). Based on PGA, the clinical remission and clinical response rates were 24% and 55% respectively. Withdrawal of corticosteroids was observed in 70.8% of steroid-dependent patients at the end of the study. Three out of 10 clinical non-responders needed a colectomy. Mean fecal calprotectin value at baseline was 300 μg/g, and 170.5 μg/g at wk 14. Being anti-TNF treatment na?ve was a protection factor, which was related to better chances of reaching clinical remission. Twenty-seven point three percent of the patients required treatment intensification at 14 wk of followup. Only three adverse effects(AEs) were observed during the study; all were mild and golimumab was not interrupted.CONCLUSION This real-life practice study endorses golimumab's promising results, demonstrating its short-term effectiveness and confirming it as a safe drug during the induction phase. | Marta Maia Bosca-Watts Xavier Cortes Marisa Iborra Jose Maria Huguet Laura Sempere Gloria Garcia Rafa Gil Mari Fe Garcia Marga Munoz Pedro Almela Nuria Maroto Jose Maria Paredes | 2016 | World Journal of Gastroenterology2016，22，47： | 5 |
| 2 | Identification of serum and tissue micro‐ RNA expression profiles in different stages of inflammatory bowel disease显示文摘 | M. Iborra F. Bernuzzi C. Correale S. Vetrano G. Fiorino B. Beltrán F. Marabita M. Locati A. Spinelli P. Nos P. Invernizzi S. Danese | 2013 | Clin Exp Immunol2013，，2： | 4 |
| 3 | Small intestinal bacterial overgrowth in inactive Crohn's disease:Influence of thiopurine and biological treatment显示文摘AIM:To investigate the influence of thiopurines and biological drugs on the presence of small intestinal bacterial overgrowth(SIBO) in patients with inactive Crohn's disease(CD).METHODS:This was a prospective study in patients with CD in remission and without corticosteroid treatment,included consecutively from 2004 to 2010.SIBO was investigated using the hydrogen glucose breath test.RESULTS:One hundred and seven patients with CD in remission were included.Almost 58%of patients used maintenance immunosuppressant therapy and 19.6%used biological therapy.The prevalence of SIBO was16.8%.No association was observed between SIBO and the use of thiopurine Immunosuppressant(12/62patients),administration of biological drugs(2/21 patients),or with double treatment with an anti-tumor necrosis factor drugs plus thiopurine(1/13 patients).Half of the patients had symptoms that were suggestive of SIBO,though meteorism was the only symptom that was significantly associated with the presence of SIBO on univariate analysis(P<0.05).Multivariate analysis revealed that the presence of meteorism and a fistulizing pattern were associated with the presence of SIBO(P<0.05).CONCLUSION:Immunosuppressants and/or biological drugs do not induce SIBO in inactive CD.Fistulizing disease pattern and meteorism are associated with SIBO. | Cristina Sánchez-Montes Vicente Ortiz Guillermo Bastida Ester Rodríguez María Yago Belén Beltrán Mariam Aguas Marisa Iborra Vicente Garrigues Julio Ponce Pilar Nos | 2014 | World Journal of Gastroenterology2014，20，38： | 4 |
| 4 | Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients显示文摘AIM:To evaluate the effectiveness of adalimumab in preventing recurrence after intestinal resection for Crohn's disease in high-risk patients.METHODS:A multicenter,prospective,observational study was conducted from June 2009 until June 2010.We consecutively included high-risk Crohn's disease patients who had undergone an ileal/ileocolonic resection.High-risk patients were defined as two or more criteria:smokers,penetrating pattern,one or more previous surgical resections or prior extensive resection.Subcutaneous adalimumab was administered 2 wk(± 5 d) after surgery at a dose of 40 mg eow,with an initial induction dose of 160/80 mg at weeks 0 and 2.Demographic data,previous and concomitant treatments(antibiotics,5-aminosalicylates,corticosteroids,immunomodulators or biologic therapies),smoking status at the time of diagnosis and after the index operation and number of previous resections(type and reason for surgery) were all recorded.Biological status was assessed with C-reactive protein,erythrocyte sedimentation rate and fecal calprotectin.One year(± 3 mo) after surgery,an ileocolonoscopy and/or magnetic resonance enterography was performed.Endoscopic recurrence was defined as Rutgeerts score ≥ i2.Morphological recurrence was based on magnetic resonance(MR) score ≥ MR1.RESULTS:Twenty-nine patients(55.2% males,48.3% smokers at diagnosis and 13.8% after the index operation),mean age 42.3 years and mean duration of the disease 13.8 years were included in the study.A mean of 1.76(range:1-4) resections previous to adalimumab administration and in 37.9% was considered extensive resection.51.7% had previously received infliximab.Immunomodulators were given concomitantly to 17.2% of patients.Four of the 29(13.7%) developed clinical recurrence,6/29(20.7%) endoscopic recurrence and 7/19(36.8%) morphological recurrence after 1-year.All patients with clinical recurrence showed endoscopic and morphological recurrence.A high degree of concordance was found between clinical-endoscopic recurrence(k = 0.76,P < 0.001) and clinical-morphological recurrence(k = 0.63,P = 0.003).Correlation between endoscopic and radiological findings was good(comparing the 5-point Rutgeerts score with the 4-point MR score,a score of i4 was classified as MR3,i3 as MR2,and i2-i1 as MR1)(P < 0.001,r s = 0.825).During follow-up,five(17.2%) patients needed adalimumab dose intensification(40 mg/wk);Mean time to intensification after the introduction of adalimumab treatment was 8 mo(range:5 to 11 mo).In three cases(10.3%),a biological change was needed due to a worsening of the disease after the dose intensification to 40 mg/wk.One patient suffered an adverse event.CONCLUSION:Adalimumab seems to be effective and safe in preventing postoperative recurrence in a selected group of patients who had undergone an intestinal resection for their CD. | Mariam Aguas Guillermo Bastida Elena Cerrillo Belén Beltrán Marisa Iborra Cristina Sánchez-Montes Fernando Muoz Jesús Barrio Sabino Riestra Pilar Nos | 2012 | World Journal of Gastroenterology2012，18，32： | 3 |
| 5 | Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis显示文摘 | Iborra S Soto M Carrion J | 2004 | Vaccine2004，22，2930： | 1 |
| 6 | , Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 non- randomized comparative trial with radical cystectomy显示文摘 | SOLSONA E CLIMENT MA IBORRA I | 2009 | Eur Urol2009，55，4： | 1 |
| 7 | Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder Cancer显示文摘 | Eduardo Solsona Inmaculada Iborra Argimiro Collado José Rubio-Briones Juan Casanova Ana Calatrava | 2010 | The Journal of Urology2010，，2： | 1 |
| 8 | Biomass into chemicals: aerobic oxidation of 5-hydroxymethyl-2-furfural into 2,5-furandicarboxylic acid with gold nanoparticle catalysts 显示文摘 | CASANOVA O IBORRA S CORMA A | 2009 | ChemSusChem2009，2，12： | 1 |
| 9 | Feasibility of transure- thral resection for muscle infiltrating carcinoma of the blad der~long-term follow-up of a prospective study显示文摘 | Solsona E Iborra L Ricos J | 1998 | J Urol1998，159，： | 1 |
| 10 | Conversion of biomass platform molecules into fuel additives and liquid hydrocarbon fuels显示文摘 | Climent M J Corma A Iborra S | 2014 | Green Chemistry2014，16，： | 1 |
| 11 | Effects of polyols on a-ehymotrypsin thermostability a mechanistic analysis of the enzyme stabilization显示文摘 | Lozano P Combes D Iborra J L | 1994 | Journal of bioteehnology1994，35，： | 1 |
| 12 | Chemical routes for the trans- formation of biomass into chemicals 显示文摘 | Corma A Iborra S Velty A | 2007 | Chem Rev2007，107，： | 1 |
| 13 | Fluorescence and CD spectroscopic analysis of the α-chymotrypsin stabilization by the ionic liquid, 1-ethyl-3-methylimidazolium bis amide显示文摘 | Diego T D Lozano P Gmouh S Vaultier M Iborra J L | 2004 | Biotechnol Bioeng2004，88，： | 1 |
| 14 | Chemical routes for the transformation of biomass into chemicals 显示文摘 | Corma A Iborra S Velty A | 2007 | Chem Rev2007，107，6： | 1 |
| 15 | Chemical routes for the transformation of biomass into chemicals显示文摘 | CORMA A IBORRA S VELTY A | 2007 | Chem Rev2007，107，6： | 1 |
| 16 | Chemical routes for the transformation of biomass into chemicals 显示文摘 | Corma A Iborra S Velty A | 2007 | Chemical Reviews2007，107，24： | 1 |
| 17 | Effect of oxidation agents on reverse osmosis membrane performance to brackish water desalination显示文摘 | Iborra M L Lora J | 1996 | Desalination1996，108，： | 1 |
| 18 | Direct repair of spondylolysis using a new pedicle screw hook fixation:clinical and CT-assessed study:an analysis of 19 patients显示文摘 | Roca J Iborra M Cavanilles-Walker JM | 2005 | J Sspinal Disord Tech2005，18，： | 1 |
| 19 | Synthesis of transportation fuels from bio,nass:chemisty, catalysts, and engineering 显示文摘 | HUBER GW IBORRA S CORMA A | 2006 | Chemieal Reviews2006，106，9： | 1 |
| 20 | Mass spectrometry analysis of the oligomeric C1q protein reveals the B chain as the target of trypsin cleavage and interaction with fucoidan显示文摘 | Tissot B Gonnet F Iborra A | 2005 | Bio-chemistry2005，44，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员